BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that it will be participating in the Targeted Radiopharmaceuticals Summit being held virtually December 8th – 10th.

Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy results demonstrating that DNA medicine VGX-3100,

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it is the first company to offer clients Good Laboratory Practices (GLP) validated digital peer review using Deciphex Patholytix Preclinical for toxicologic pathology. Through its partnership with Deciphex

Day Zero Diagnostics Doubles Down on epiXact ® Service for Investigating Healthcare-Associated Infection Outbreaks Supported by New NIH Funding Award SBIR Phase I Funds to Boost Speed of the Company’s Robust Sequencing and Analysis Service for Infection Control Professionals BOSTON--( BUSINESS WIRE )-- Day Zero Diagnostics, Inc. , an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat

CG Oncology, Inc. , a clinical-stage immuno-oncology company, today announced the first patient has been dosed in CORE1, a Phase 2 clinical trial of CG0070 in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). “We are motivated to advance this crucially important program, despite the challenges present

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with POINT Biopharma, Inc

Data presented at SABCS indicates benefits of oral paclitaxel and encequidar (oral paclitaxel) versus IV paclitaxel (IV P ) on Progression-Free Survival (PFS) and on Overall Survival (OS), which suppor ts superiority o n the primary endpoint Overall Response Rate (ORR) . In the intent - to - treat ( I TT) population, oral paclitaxel showed a benefit on PFS versus IVP , and showed a trend favoring oral paclitaxel on OS versus IVP.

Collaboration aims to accelerate the development and translation of Yale’s research and innovation projects to a decision point

Humacyte President and CEO Laura Niklason, M.D., Ph.D. will speak at the renowned Milken Institute Future of Health Summit on Wednesday, December 9 at 1:30 p.m. EST.